Prime Medicine
Prime Medicine raises $315M Series B at $1.85B valuation
Prime Medicine: Series B Funding Round
Prime Medicine has successfully raised $315M in Series B funding, reaching a valuation of $1.85B.
Company Overview
Prime editing gene therapy
Funding Details
The Series B round was led by GV, with participation from F-Prime Capital, Westlake Village BioPartners, ARCH Venture Partners, Deerfield Management.
Company Information
- Headquarters: 800 Boylston Street, Boston, MA 02199
- Founded: 2019
- Employees: 250+
- Category: Biotech
Investment
Prime Medicine plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- GV: Verified investor in Series B
- F-Prime Capital: Verified investor in Series B
- Westlake Village BioPartners: Verified investor in Series B
- ARCH Venture Partners: Verified investor in Series B
- Deerfield Management: Verified investor in Series B
Company Info
Investors (5)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free